Sophoricoside
Based on 4 publication(s) in Google Scholar
Sophoricoside is an isoflavone glycoside isolated from Sophora japonica and has anti-inflammatory, anti-cancer and immunosuppressive effects.
For research use only. We do not sell to patients.
- Purity: 99.57%
- CAS No.: 152-95-4
- Formula: C21H20O10
- Molecular Weight:432.38
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Sophoricoside
More
Biological Activity
Sophoricoside is an isoflavone glycoside isolated from Sophora japonica and has anti-inflammatory, anti-cancer and immunosuppressive effects. The results show that Sophoricoside (50 μM) significantly inhibits the PMACI-induced histamine release. The inhibition rate reaches up to 30.24%. The maximal rates of TNF-α, IL-8 and IL-6 inhibition by Sophoricoside (50 μM) are approximately 31.42%, 43.43% and 34.24%, respectively. The rates of the levels of Rel/p65 inhibition in nuclear by Sophoricoside (50 μM) is approximately 50.14%. Results show that the enhanced caspase-1 activity induced by PMACI is significantly reduced by Sophoricoside in a dose-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 152-95-4
-
Appearance Solid
-
Molecular Weight 432.38
-
Formula C21H20O10
-
Color White to light brown
-
SMILES
OC1=CC(O)=C(C(C(C2=CC=C(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C=C2)=CO4)=O)C4=C1
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
NPJ Precis Oncol
METTL21A promotes hepatocellular carcinoma progression via methylating and stabilizing BAG3. [Abstract]2025 Jul 10;9(1):234. PMID: 40640484 -
Int J Mol Med
Sophoricoside attenuates autoimmune‑mediated liver injury through the regulation of oxidative stress and the NF‑κB signaling pathway. [Abstract]2023 Sep;52(3):78. PMID: 37477163 -
Neuropsychopharmacology
Small-molecule natural product sophoricoside reduces peripheral neuropathic pain via directly blocking of NaV1.6 in dorsal root ganglion nociceptive neurons. [Abstract]2025 Mar;50(4):662-672. PMID: 39414988 -
Coron Artery Dis
Sophoricoside enhances reparative macrophage polarization to promote cardiac repair postmyocardial infarction through PPAR-γ. [Abstract]2025 Jul 21. PMID: 40689420
Solvent & Solubility
DMSO : 41.67 mg/mL (96.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (4.81 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.81 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Cells are incubated with the Sophoricoside for 1 h, and then incubated with PMACI for 2 h. The reaction is stopped by cooling the tubes in ice. The cells are separated from the released histamine by centrifugation at 400×g for 5 min at 4°C. The histamine levels are measured by ELISA using a histamine assay kit according to the manufacturer’s directions. Duplicate aliquots of supernatant are measured for each sample[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
To test the cell viability by each concentration of Sophoricoside, the MTT colorimetric assay is performed. Briefly, HMC-1 cells (3×105 cells/well) are incubated with Sophoricoside (1 to 50 μM) for 12 h. After the addition of MTT solution, the cells are incubated at 37°C for 4 h. The crystallized MTT (formazan) is dissolved in dimethyl sulfoxide and the absorbance is measured at 540 nm[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
BALB/c mice (5 weeks, 19 to 20 g) are used in this study. The dorsal skin of the BALB/c mice (n=6) is shaved and treated with a depilatory prior to the experiment. The mice are sensitized with 100 μL of 0.15% DNCB in acetone-olive oil (3:1) applied to the dorsal skin twice per week for 5 weeks. Control mice receive vehicle (acetone/olive oil=3:1). After 3 weeks, Sophoricoside (2 mg/kg) is orally administered 2 weeks until the end of the experiment[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3128 mL | 11.5639 mL | 23.1278 mL | 57.8195 mL |
| 5 mM | 0.4626 mL | 2.3128 mL | 4.6256 mL | 11.5639 mL | |
| 10 mM | 0.2313 mL | 1.1564 mL | 2.3128 mL | 5.7820 mL | |
| 15 mM | 0.1542 mL | 0.7709 mL | 1.5419 mL | 3.8546 mL | |
| 20 mM | 0.1156 mL | 0.5782 mL | 1.1564 mL | 2.8910 mL | |
| 25 mM | 0.0925 mL | 0.4626 mL | 0.9251 mL | 2.3128 mL | |
| 30 mM | 0.0771 mL | 0.3855 mL | 0.7709 mL | 1.9273 mL | |
| 40 mM | 0.0578 mL | 0.2891 mL | 0.5782 mL | 1.4455 mL | |
| 50 mM | 0.0463 mL | 0.2313 mL | 0.4626 mL | 1.1564 mL | |
| 60 mM | 0.0385 mL | 0.1927 mL | 0.3855 mL | 0.9637 mL | |
| 80 mM | 0.0289 mL | 0.1445 mL | 0.2891 mL | 0.7227 mL |